by The global Sacroiliac Joint Fusion market size is expected to be worth around US$ 761.45 million by 2030, according to a new report by Vision Research Reports.
The global Sacroiliac Joint Fusion market size was valued at US$ 190.5 million in 2020 and is anticipated to grow at a CAGR of 18.5% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39013
Growth Factors
Growing technological developments, the number of minimally invasive surgical procedures, reimbursement coverage, and initiatives by key companies are some of the key drivers of this market. As per AmeriHealth Caritas, by 2020, minimally invasive sacroiliac joint fusion was covered by Medicaid programs in 44 states in the U.S. while 32 Blue Cross Blue Shield plans covered minimally invasive joint fusion by 2019. This is anticipated to increase the number of MIS sacroiliac joint fusion procedures.
The COVID-19 pandemic resulted in logistical bottlenecks, decreased sales and marketing activities, low demand, and other challenges for market participants. The major impact during the pandemic, however, was canceled or postponed elective surgeries. As many countries went under lockdown and implemented movement restrictions, the number of elective surgeries plummeted. In addition, several healthcare institutions and regulatory bodies recommended the postponement of elective surgical procedures.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 761.45 million by 2030 |
| Growth Rate | CAGR of 18.5% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Indication, Surgery Type, Product, End-user |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | SI-BONE, Inc.; SIGNUS Medizintechnik GmbH; Globus Medical; Orthofix Medical Inc.; Life Spine, Inc.; Camber Spine Technologies, LLC; CoreLink Surgical; Xtant Medical; Surgalign Spine Technologies, Inc.; Medtronic |
By Indication Analysis
The degenerative sacroilitis segment held the largest revenue share of over 35.0% in 2020. The key factors contributing to this segment growth include a high prevalence of degenerative sacroilitis, growing awareness regarding the condition, and improving diagnostic capabilities for sacroiliac joint disorders.
The trauma segment is expected to expand at the highest CAGR of 18.7% from 2021 to 2030. Trauma indication is one of the most recently approved indications by the FDA, thus contributing to the segment growth.
By Surgery Type Analysis
The minimally invasive surgeries (MIS) segment held the largest revenue share of over 91.0% in 2020 and is estimated to expand at the fastest growth rate over the forecast period. The increasing preference for minimally invasive surgeries due to associated benefits such as smaller incisions.
According to the Washington State Health Care Authority’s 2021 report, minimally invasive SI joint fusion surgery was found to be more effective than open fusion for reducing pain. It is also associated with a shorter length of stay at the hospital.
By Product Analysis
The implants segment accounted for the largest revenue share of over 70.0% in 2020 and is projected to expand at the highest CAGR over the forecast period. The key factors contributing to the segment growth include the rising demand for safe and effective sacroiliac joint fusion systems and advancements in technology and materials used in these systems.
3D printing technology is gaining popularity in various applications of MIS such as bio modeling to optimize preoperative planning, manufacturing of implants, and hardware templates and guides.
By End-user Analysis
The hospitals segment dominated the market with a revenue share of over 45.0% in 2020. The key factors contributing to the segment growth include a higher volume of surgeries performed in hospitals and a growing preference for minimally invasive surgeries.
According to the Centers for Medicare & Medicaid Services (CMS), in March 2021, there were around 187 Medicare-certified ASCs in Washington state, 442 in Texas, 457 in Florida, 817 in California, and 368 in Georgia. In fact, as per Definitive Healthcare, LLC, there were about 9,280 active ASCs in 2019 in the U.S. These numbers are anticipated to increase over the forecast period.
By Regional Analysis
North America held the largest revenue share of over 40.0% in 2020. The growth of the regional market can be attributed to the presence of key players, advanced healthcare infrastructure, and growing reimbursement coverage. Asia Pacific is projected to expand at the fastest CAGRof 19.1% over the forecast period.
SI-BONE, Inc. reported the first iFuse procedures beyond its key markets of Europe and the U.S., in countries such as Canada, Israel, Japan, Australia, Hong Kong, New Zealand, Saudi Arabia, South Africa, and Turkey, thus expanding its regional presence.
Key Players
- SI-BONE, Inc.
- SIGNUS Medizintechnik GmbH
- Globus Medical
- Orthofix Medical Inc.
- Life Spine, Inc.
- Camber Spine Technologies, LLC
- CoreLink Surgical
- Xtant Medical
- Surgalign Spine Technologies, Inc.
- Medtronic
Market Segmentation
- By Indication
- Degenerative Sacroilitis
- Sacral Disruption
- Trauma
- By Surgery Type
- MIS
- Open
- By Product
- Implants
- Accessories
- By End-user
- Hospitals
- Ambulatory Surgical Centers
- Others (Specialty Centers, Research & Academic Institutes)
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Asia Pacific
- China
- India
- Japan
- Latin America
- Brazil
- Mexico
- MEA
- South Africa
- Saudi Arabia
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Product Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Sacroiliac Joint Fusion Market, By Indication
7.1. Sacroiliac Joint Fusion Market, by Indication, 2021-2030
7.1.1. Degenerative Sacroilitis
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Sacral Disruption
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Trauma
7.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Sacroiliac Joint Fusion Market, By Surgery Type
8.1. Sacroiliac Joint Fusion Market, by Surgery Type, 2021-2030
8.1.1. MIS
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Open
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Sacroiliac Joint Fusion Market, By Product
9.1. Sacroiliac Joint Fusion Market, by Product, 2021-2030
9.1.1. Implants
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Accessories
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Sacroiliac Joint Fusion Market, By End-user
10.1. Sacroiliac Joint Fusion Market, by End-user, 2021-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Ambulatory Surgical Centers
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others (Specialty Centers, Research & Academic Institutes)
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Sacroiliac Joint Fusion Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Indication (2017-2030)
11.1.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.1.3. Market Revenue and Forecast, by Product (2017-2030)
11.1.4. Market Revenue and Forecast, by End-user (2017-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Product (2017-2030)
11.1.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Indication (2017-2030)
11.1.6.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.1.6.3. Market Revenue and Forecast, by Product (2017-2030)
11.1.6.4. Market Revenue and Forecast, by End-user (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Indication (2017-2030)
11.2.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.2.3. Market Revenue and Forecast, by Product (2017-2030)
11.2.4. Market Revenue and Forecast, by End-user (2017-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Product (2017-2030)
11.2.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Indication (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Product (2017-2030)
11.2.6.4. Market Revenue and Forecast, by End-user (2017-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Indication (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Product (2017-2030)
11.2.7.4. Market Revenue and Forecast, by End-user (2017-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Indication (2017-2030)
11.2.8.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.2.8.3. Market Revenue and Forecast, by Product (2017-2030)
11.2.8.4. Market Revenue and Forecast, by End-user (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Indication (2017-2030)
11.3.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.3.3. Market Revenue and Forecast, by Product (2017-2030)
11.3.4. Market Revenue and Forecast, by End-user (2017-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Product (2017-2030)
11.3.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Indication (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Product (2017-2030)
11.3.6.4. Market Revenue and Forecast, by End-user (2017-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Indication (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Product (2017-2030)
11.3.7.4. Market Revenue and Forecast, by End-user (2017-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Indication (2017-2030)
11.3.8.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.3.8.3. Market Revenue and Forecast, by Product (2017-2030)
11.3.8.4. Market Revenue and Forecast, by End-user (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Indication (2017-2030)
11.4.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.4.3. Market Revenue and Forecast, by Product (2017-2030)
11.4.4. Market Revenue and Forecast, by End-user (2017-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Product (2017-2030)
11.4.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Indication (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Product (2017-2030)
11.4.6.4. Market Revenue and Forecast, by End-user (2017-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Indication (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Product (2017-2030)
11.4.7.4. Market Revenue and Forecast, by End-user (2017-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Indication (2017-2030)
11.4.8.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.4.8.3. Market Revenue and Forecast, by Product (2017-2030)
11.4.8.4. Market Revenue and Forecast, by End-user (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.5.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.5.3. Market Revenue and Forecast, by Product (2017-2030)
11.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Product (2017-2030)
11.5.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Indication (2017-2030)
11.5.6.2. Market Revenue and Forecast, by Surgery Type (2017-2030)
11.5.6.3. Market Revenue and Forecast, by Product (2017-2030)
11.5.6.4. Market Revenue and Forecast, by End-user (2017-2030)
Chapter 12. Company Profiles
12.1. SI-BONE, Inc.
12.1.1. Company Overview
12.1.2. Indication Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. SIGNUS Medizintechnik GmbH
12.2.1. Company Overview
12.2.2. Indication Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Globus Medical
12.3.1. Company Overview
12.3.2. Indication Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Orthofix Medical Inc.
12.4.1. Company Overview
12.4.2. Indication Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Life Spine, Inc.
12.5.1. Company Overview
12.5.2. Indication Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Camber Spine Technologies, LLC
12.6.1. Company Overview
12.6.2. Indication Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. CoreLink Surgical
12.7.1. Company Overview
12.7.2. Indication Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Xtant Medical
12.8.1. Company Overview
12.8.2. Indication Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Surgalign Spine Technologies, Inc.
12.9.1. Company Overview
12.9.2. Indication Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Medtronic
12.10.1. Company Overview
12.10.2. Indication Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39013
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
